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Introduction
Our goals in medicine are (i) to improve the quality of patients’ lives,
(ii) help them to live longer, and (iii) to do so at a reasonable cost.
These are our true endpoints: health status, survival, and cost. It is
thus entirely consistent with this point of view that these are the fun-
damental concepts that can be united in a formal cost–utility ana-
lysis.1 These endpoints remain the best measures of efficacy in
clinical trials comparing a new therapy to placebo or to an active
control. All other measures may then be seen as surrogate endpoints
or surrogates. Thus, even serious events such as myocardial infarc-
tion and stroke may be considered surrogates, as their effect is to
adversely affect the critical endpoints of health status, survival, and
cost. However, in common usage a surrogate is a relatively easy to
measure endpoint, available over a relatively short timeframe that
is used in place of the true endpoints.
Generally, surrogates are not events, but rather measurements
(physiological, laboratory, or test results, e.g. biomarkers) that
predict events. Thus, surrogates are most commonly measures that
we can record, often with much shorter timescales than is necessary
forevents.2 Surrogates are usually continuous variables, often but not
necessarily with reasonable approximations of a normal distribution.
Continuous variables, especially if approximating a normal distribu-
tion, will allow for much smaller sample sizes than dichotomous vari-
ables as well as shorter periods of follow-up and lower costs. Thus,
compared with clinical outcome trials, studies with surrogate
endpoints can be conducted rapidly and with much less resource
use and expense than endpoint studies. Surrogates can be used in
observational studies as well as in randomized trials. For instance,
low-density lipoprotein cholesterol could be used as a surrogate
for cardiovascular events in a non-interventional observational
study. However, the most common and perhaps most critical issue
is the use of surrogate endpoints in randomized trials comparing
different therapies.
Potential surrogates
Any surrogate should be consistently measurable and sensitive to the
intervention.3 In Table 1, we reproduce and modify a list of potential
surrogates including physical exam as well as haemodynamic, blood,
imaging, and other testing.2 This list is not meant to be exhaustive, but
rather to reflect potential surrogates in different areas of cardiovas-
cular medicine: Hypertension, lipid disorders, diabetes, coronary
artery disease, acute coronary syndromes, heart failure, and ECG ab-
normalities. We give an approximate, perhaps somewhat arbitrary
rank to each variable’s validity as a true surrogate. A surrogate is
most useful when it (i) consistently predicts events in the future
and (ii) if the response of the surrogate to an intervention predicts
the response to the intervention in an endpoints trial.
Hypertension
The variable perhaps most often thought of as a consistently useful
surrogate in interventional trials is the simple measurement of
blood pressure. Lowering blood pressure using different therapies
has consistently resulted in reduced events, in particular stroke.4
However, even this relationship is not straight forward. For instance,
while blood pressure is related to event rates to pressures
,120 mmHg systolic, there is insufficient evidence that lowering
blood pressure with pharmaceutical in patients with hypertension
to ,140 mmHg systolic will reduce event rates.5 Furthermore, in
some trials similar blood pressure reduction led to different effects
on hard endpoints such as mortality and stroke.6,7 Other measures
of vascular physiology are less reliable. Despite its limitations,
blood pressure remains a useful surrogate as recognized in the
current guidelines from the Joint National Committee as well as
the European Society of Cardiology; blood pressure level remains a
therapeutic goal.4,8 However, blood pressure may not be useful in
all clinical situations. For instance, blood pressure will fall in patients
with a history of hypertension who develop heart failure. In this
common clinical scenario, blood pressure will no longer be a useful
surrogate.
Lipids
Low-density lipoprotein (LDL) cholesterol is the most useful surro-
gate lipid measure, given the many trials with statins that demon-
strated both reduced LDL cholesterol as well as cardiovascular
events. While, the efficacy of other agents to reduce event rates by
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reducing LDL cholesterol is not as well established, recent data have
shown both LDL and event rate reduction with ezetimibe as well as
early data with PCSK9 antibodies.9– 12 Nonetheless, it is possible that
the mechanismby which statins reduce event ratesmay not beentire-
ly by their effects on LDL cholesterol alone; statins also exert
pleiotrophic effects on small G proteins among other effects.13 Of
importance, there remains some uncertainty about target levels for
LDL as the endpoint trials did not include target levels for LDL;
leading to target levels no longer being recognized in the 2013 Guide-
lines from the American College of Cardiology and the American
Heart Association.14 However, the European Society of Cardiology
guidelines have maintained such an approach.15,16
High-density lipoprotein (HDL) cholesterol plasma levels have
been shown to predict events in epidemiological studies, but the
event outcome data on pharmaceuticals to raise HDL have been
unconvincing. Indeed, it appears that the biological activity of HDL
cholesterol changes in patients with diabetes, coronary artery
disease, and acute coronary syndromes, most likely due to a
change on its proteome composition.17–19 Surrogates related to
atherosclerosis, including imaging such as calcium scoring and
carotid ultrasound are also at best uncertain.20,21
Diabetes
Diabetes is clearly a risk factor for cardiovascular events.22,23
However, there is little evidence that tight control of diabetes will
reduce cardiovascular events.24 Indeed, recent trials showed that
lowering haemoglobin 1Ac with blood sugar lowering drugs such
as DDP-4 inhibitors or strict lifestyle measuresdid not reduce cardio-
vascular events.25–27
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Table 1 Potential surrogate endpoints in clinical trials
Disease area Potential surrogate endpoint Validity as a true surrogate
Hypertension/vascular physiology Blood pressure8 ++++
Carotid intima-media thickness8 ++
Microalbuminuria8,15 ++/?
Flow-mediated dilatation58,59 ++
Left ventricular hypertrophy8 ++
Lipid disorders/atherosclerosis Low-density lipoprotein cholesterol9,10,15,57 ++++
High-density lipoprotein cholesterol11,12 2
Carotid magnetic resonance imaging60 ++
Intravascular ultrasound20 ++
Coronary computed tomography61 ?
Optical coherence tomography62 ?
Diabetes Serum glucose ++
Haemoglobin A1c ++
Microalbuminuria ++
Obstructive coronary artery disease Quantitative coronary angiography63 ++
Intravascular ultrasound20 ++
Coronary computed tomography61 ?
Optical coherence tomography62 ?
Restenosis after PCI28–30 ++
Angiographic variables to predict restenosis31,32 +
Acute coronary syndromes Troponins64 ++
Brain natriuretic peptide64 ++
Infarct size65 ?
Return of TIMI flow66,67 ?
Resolution of ST elevation67 ?
Heart failure Exercise capacity68,69 2
Haemodynamics (e.g. cardiac output)69 2
Ejection fraction33 ++
Remodelling (e.g. LV volume)70 ++
Brain natriuretic peptide69,71 2
Electrophysiology Premature ventricular beats36 2
Late potentials72 2
Non-sustained ventricular tachycardia36 TTaTachycardia 2
The symbols ‘2‘ and ‘+’ to ‘+ ++ +’ indicate the reliability of the potential surrogate; the symbol ‘?’ indicates currently unknown. A valid surrogate or true surrogate will be on the
causal path to and have a strong, consistent statistical relationship with the clinical endpoint.
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Coronary disease
Measures of the extent and severity of coronary artery disease noted
in Table 1 are also mixed as surrogates. While the extent of coronary
artery diseasenotedonangiogramshasbeen showntopositively cor-
relate with cardiovascular events, the angiogram is more useful as a
guide to therapy than as a surrogate outcome. Other measures of
coronary disease are also uncertain surrogates. Measures of acute
coronary syndromes, such as troponins are useful diagnostically to
guide therapy, but have not proven useful as surrogate endpoint
for events in randomized trials. Restenosis after PCI is a surrogate
forqualityof life andmyocardial infarction.28– 30 Variousangiographic
measures have also been used as surrogates for restenosis or target
lesion revascularization.31,32
Heart failure
There are inadequate potential surrogates in heart failure.33 In par-
ticular, changes in exercise capacity, haemodynamic variables, and
ejection fraction have failed to predict clinical outcome. Thus, al-
though the ejection fraction predicts outcome, changes thereof
under treatment with inotropes may even be associated with an in-
crease in mortality.34 Somewhat paradoxically, b-blockers, in spite
of their negative inotropic effects, result in a slightly improved ejec-
tion fraction over time, and improved survival.35 Thus, we cannot
use ejection fraction or any other measure of improved left ventricu-
lar performance as a reliable surrogate in heart failure trials.
Electrocardiogram
Findings on the ECG may also predict events, but have not been re-
liable as guides to effectiveness of therapy. Perhaps the best known
failure is this endpoint is that suppression of premature ventricular
contractions (PVCs) post-MI by class I anti-arrhythmic agents will
not reduce events, but rather enhanced mortality.36
Why surrogates fail
Apotential surrogate isoftenconsideredas an intermediateendpoint
in aclinical trial because it is found topredictoutcome in observation-
al studies. Thus, blood pressure and LDL cholesterol are well known
(and in fact accepted by regulatory agencies such as the Federal Drug
Administration or the European Medical Agency) to predict
outcome, and have been used as surrogate endpoints in clinical
trials. Indeed, clinical outcome studies did show that interventions
which favourably affected these surrogates did in general reduce
the incidence of cardiovascular events.
However, there are also many examples where a therapy was
shown to favourably affect a surrogate, but was not found to
reduce cardiovascular events. Thus, serum HDL cholesterol level
has an inverse relationship with cardiovascular events. Furthermore,
both niacin and cholesterol ester transfer protein blockers have been
shown to increase serum HDL cholesterol.11,12,37 Nonetheless,
recent trials with these agents have not shown efficacy in reducing
cardiovascular events; indeed, one of them even increased mortality
in spite of marked increases in HDL cholesterol.12
As noted above, while PVCs noted on the ECG post myocardial
infarction predict events, a trial of anti-arrhythmic agents which
reduce PVCs failed to show efficacy in preventing events.36
As a third example, hormone replacement therapy in post-
menopausal women will favourably affect the serum lipid profile.
However, randomized trials of hormone replacement therapy have
not been shown to reduce cardiovascular events.38 It is also possible
that the problemwith a therapy thatworks ona surrogatebut failed in
an outcomes trial was due to inadequate dosing, too short a time
period, an inappropriate patient population or too small a population.
Causality
Why do some potential surrogates seem to work well, while others
fail? We can gain insight by considering the nature of causality.39,40 A
true surrogate should be in the causal path of a true endpoint. Thus,
LDL cholesterol is a good candidate true surrogate, as high LDL
causes more events by directly augmenting atherosclerotic plaque
formation, a prime culprit for myocardial infarction and cardiovascu-
lar death. On the other hand, lowering LDL causes the event rate to
be lower as it reduces the lipid content of plaques and hence the vul-
nerability of plaques. To establish causation requires a deep under-
standing of the pathophysiology of the disease process and hence is
a stronger criterion than just noting an association. If there is associ-
ation but not causation, then the relationship between a surrogate
and outcome events may be confounded. A confounder is a variable
that predicts outcomes and has higher prevalence in the group with
the potential surrogate of interest.39 Thus, PVCs may be confounded
by left ventricular function,wherebypatientswith left ventriculardys-
function have more PVCs, and it may be the left ventricular dysfunc-
tion which causes increased mortality. If this is the case, a drug which
decreases PVCs may have no effect on left ventricular function and
thus may not exert any effect on subsequent mortality.36
A true surrogate will always be affected before the clinical end-
point as it often precedes late disease states that lead to myocardial
infarction, stroke, or death. However, it is wrong to think that a tem-
poral relationship is all that is necessary to establish causality. This has
been recognized since ancient times as noted by the famous humor-
ous statement – ‘post hoc ergo propter hoc’, which is Latin for ‘after
this, therefore because of this’. Temporality is just one component of
what is necessary to consider causal relationship.
This was considered by pioneering British epidemiologist and stat-
istician Austin Bradford Hill. In the 1950sDoll and Hill41,42 publisheda
pair of sentinel papers showing the association between cigarette
smoking and lung cancer. These papers, plus data from Framingham
on the impact of cigarette smoking on cardiovascular disease risk,43
helped move the US Federal Government in 1964 to issue the first
Surgeon General’s Report on Smoking and Health.44,45 Nonetheless,
before the 1960s there was controversy over whether cigarette
smoking was causally related to lung cancer as opposed to just
being an association. Hill considered the steps necessary to establish
a causal relationship between any risk factor, i.e. surrogate, and future
events.46 The Bradford Hill criteria are: (i) temporal relationship, the
cause must always come before the effect, (ii) strength of association,
(iii) dose–response relationship, (iv) consistency of the relationship,
(v) biological plausibility, (vi) consideration of alternatives, (vii) ex-
perimental verification, (viii) specificity, that is a specific cause for a
specific effect, and (ix) coherence, that is compatible with existing
knowledge.39,46 Specificity is often omitted as it is generally not
fulfilled for diseases which may have multiple causes. Establishing
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causality requires consideration of these criteria, and then general
acceptance by the scientific community and society at large. Now a
surrogate need not be the root cause of the endpoint, but it should
be on the causal path. The Bradford Hill criteria can provide useful
guidance in this respect. For instance, if we consider whether LDL
cholesterol, we may note that it fulfils these criteria, perhaps with
the exception of specificity.
In Figure 1, we offer a conceptual model of the various ways in
which the relationship between a potential surrogate and a clinical
endpoint on a causal path can occur. In Figure 1A, we have a true sur-
rogate which is in the causal path, with the intervention occurring
earlier in the causal path, and thus eliciting a response in both the sur-
rogate and endpoint. This is the only type of relationship in which the
surrogate will be reliable. This is perhaps most clearly demonstrated
in therapy for hypertension, where pharmaceutical therapy reduces
blood pressure and reduces the incidence of strokes. The Bradford
Hill criteria would also suggest that a blood pressure response to
treatment is in the causal path to cardiovascular events. In Figure 1B,
the potential surrogate is in the causal path, but the intervention is
downstream of the surrogate. In this case, the intervention affects
the outcome but not the surrogate. For instance, coronary athero-
sclerosis is in causal path leading to cardiovascular death. However,
an intervention such as aspirin may occur downstream, preventing
the outcome but not affecting the surrogate. In Figure 1C, the poten-
tial surrogate is in the causal path, but the intervention only affects the
surrogate. This could explain why ventricular tachycardia is in the
causal path to sudden death, but anti-arrhythmic drugs may only
affect the surrogate and not prevent the endpoint. In Figure 1D, the
intervention elicits a response in both the surrogate and the
endpoint, but the surrogate is not in the causal path. This type of
situation may be unstable, and not consistently reproducible. In
Figure 1E and F, the potential surrogate is not in the causal. In
Figure 1E, the intervention only affects the surrogate and not the end-
point, and in Figure 1F, the intervention only affects the endpoint and
Figure1 Conceptual modelof the variouspossible relationships between apotential surrogate and aclinical endpoint. Only (A) is a true surrogate.
See text for explanation of the panels. Reprinted with permission from Elsevier (The Lancet 2010;376:1673).
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not the surrogate. In these latter two circumstances, the potential
surrogate is not really a surrogate at all. Figure 1G shows a more
complex scenario: a potential surrogate is in the causal pathway,
but there are other pathways to the endpoint that are independent
of the surrogate. For instance, while statins will lower LDL
cholesterol and decrease cardiovascular mortality secondary to ath-
erosclerotic disease, cardiovascular mortality may occur independ-
ently of therapy with statins and independently of LDL cholesterol.
Similarly, blood pressure elevation is on the pathway to myocardial
infarction, but there are other pathways with myocardial infarction
occurring independently of hypertension. In this setting, blood pres-
sure control may decrease the incidence of myocardial infarction
without eliminating it. Empiric data from clinical trials can show
whether an intervention affects both the surrogate and the clinical
endpoint. However, without clear understanding of the biologic
mechanisms involved it cannot be certain if the surrogate is in the
causal path. This framework around causality is conceptually
helpful, but not necessarily practical as it is often not clear for any
potential surrogate whether it is in the causal path. Thus, a more
practical empirical approach is needed.
The relationship of surrogates
to clinical endpoints
The statistical relationship of surrogates to clinical endpoints is multi-
faceted and needs careful explanation. Surrogates, such as biomar-
kers, are usually continuous variables while events are generally
binary or categorical. The relationship of a surrogate to the clinical
endpoint is more complex than that of a risk factor to an endpoint
in that a therapy’s value is based on its effect on the clinical endpoint.
If a surrogate was considered only as a risk factor, then standard
methods of discrimination (e.g. the c statistic or R2), calibration and
validation could be used. However, the key issue is whether thera-
peutic efficacy as assessed by the surrogate captures therapeutic ef-
ficacy on the clinical endpoint. The mathematical expression of this
relationship has several aspects. Prentice proposed that a surrogate
must capture any statistical relationship between the treatment and
the true endpoint.47 This would be consistent with Figure 1A,
where the surrogate and the clinical endpoint are clearly on the
causal path after the intervention. However, it is recognized that a
surrogate may not explain all of the relationship between the inter-
vention and the endpoint.48 This more complex relationship would
be consistent with Figure 1G.3 How can this relationship be explained?
An early proposal was the proportion of treatment effect (PTE) of a
clinical endpoint explained by a surrogate endpoint. Proportion of
treatment effect may be defined as (b-ba)/bwhere b and ba are, re-
spectively, the differences between treatments in a trial without and
with adjustment for the potential surrogate endpoint.49 However,
PTE is not a valid proportion as it can have values outside of the
range 0–1 (e.g. whereba is negative).49– 51 Buyse and Molenberghs52
built on these ideas to develop a pair of metrics, RE (relative effect),
which is the effect of treatment on the true endpoint relative to that
of treatment on the surrogate, and ga, which is the association
between the surrogate and true endpoint after adjustment for treat-
ment. A surrogate is perfect at the individual level if there is perfect
association between the surrogate and the true endpoint after
adjustment for treatment. A surrogate is said to be perfect at the
population level if RE ¼ 1. Buyse and Molenberghs52 initially consid-
ered the case where the outcomes of both surrogate and true end-
point were jointly normal or jointly binary in a single trial. Buyse
et al.53 extended this to meta-analyses and then Molenberghs
et al.54 extended this to mixed discrete and continuous outcomes.
The metrics which follow from these analyses are R2trial, which is the
quality of a surrogate at the trial level, andR2indiv, which is the individual
patient-level association between the surrogate and true endpoint
after adjustment for trial and treatment effects. These R2 values
range from 0 (a useless surrogate) to 1 (a perfect surrogate). Further-
more, these values are independent of the strength of the effect of
treatment on either endpoint. A practical issue is that it is necessary
to have large datasets from randomized trials to achieve good preci-
sion for these values, which is critical to permit reliable prediction of
the treatment effect on the true endpoint given the treatment effect
on the surrogate.32 Finally, estimates of these values should be vali-
dated across a number of trials to ensure consistency of the relation-
ship.32,50,54 Such mathematical expressions of the relationship
between a surrogate and true endpoint have been rarely developed
in practice.32 Further insights concerning the statistical relationship
between surrogate and clinical endpoint are offered by Weir and
Walley55 for a mathematical review and by Hughes49 for a narrative
review.
How can surrogates be used?
Given the complex relationship between interventions, surrogates,
and endpoints, how can surrogates best be used? It is unusual for a
surrogate to be so reliable that it can replace clinical endpoints for
regulatory approval and medical decision-making purposes. Studies
with surrogate endpoints will generally be much less expensive and
much more rapid to conduct than studies with clinical endpoints.
However, it is very difficult to be confident about the relationship
between the surrogate and the clinical endpoint. Studies with surro-
gates will also generally have a smaller number of patients and a
shorter time span. This limits such studies for evaluation of safety,
where safety endpoints may have no pathophysiologic relationship
with the surrogate. Thus clinical endpoint trials will remain essential,
although even endpoint trials may not have adequate power for
safety. Given problems that have been noted in the past with regula-
tory bodies approving therapies based on surrogates, it is likely that
the demand for endpoint studies for regulatory approval will be the
norm, and use of surrogates for licensing new therapies will be the
exception. Trials with surrogate endpoints that do not show efficacy
may obviate the need for endpoint trials, saving time, expense, and
avoiding unnecessary patient risk. Surrogates will remain of interest
in developing new therapies and providing pathophysiologic insight
and guiding the development of clinical endpoint trials.
For surrogates to be useful, even if only as a phase II trial rather than
a pivotal trial for registration purposes, there are several criteria to
consider (Table 2).56 Thus, the potential surrogate should be consid-
ered in specific disease states, for specific therapies and for specific
clinical outcomes. Thus, LDL cholesterol can be used as a surrogate
for statins in patients with hyperlipidaemia and the endpoint is cardio-
vascular death. Next, there should be epidemiologic evidence of as-
sociation between the surrogate and events. While blood pressure is
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an excellent example of this, HDL cholesterol, perhaps unfortunate-
ly, is as well. The surrogate should also respond to therapy consist-
ently. Thus, LDL cholesterol is consistently reduced by statins.
Next there should be a strong statistical relationship in the reduction
of clinical events explained by the surrogate. Although, realistically,
surrogates will also generally be developed without the mathematical
rigor reviewed above. Finally, the reduction of events across trials is
seen to be consistent.32 Thus, statins consistently reduce LDL chol-
esterol, and consistently reduce events (Figure 2, with permission).57
Conclusions
The use of surrogates is complex, and there is no single criterion or
standard that can readily be applied. An understanding of causality
and consideration of the relevant practical criteria is important, but
the adoption of a surrogate must always be considered on a case
by case basis. The place of surrogates in phase II trials may be reason-
able as a guide to pivotal phase three trials. However, the uncertainty
of surrogates must limit their use in phase III trials, where the unreli-
ability of surrogates alone for registration is recognized, so as to avoid
potential risk to public health.
Figure 2 The relationship between low-density lipoprotein lowering and cardiovascular events in 26 clinical trials of statins.
Table 2 Criteria for validating a surrogate
(i) Define patients, treatments, and clinical endpoints for which the
potential surrogate applies.
(ii) A strong statistical association between the surrogate and the
clinical outcome of interest.
(iii) Strong, consistent evidence of treatment differences in the
surrogate for each trial.
(iv) Treatment difference in clinical outcome within each trial is
statistically explained by the surrogate.
(v) Across trials, magnitudes of treatment difference in the surrogate
and in the clinical outcome are closely linked.
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